유전체 바이오마커 시장 - 예측(2025-2030년)

The genomic biomarkers market is projected to grow at a CAGR of 9.81% over the forecast period, increasing from US$22.631 billion in 2025 to US$36.127 billion by 2030.

Genomic biomarkers refer to measurable traits in DNA or RNA that indicate biological processes, disease mechanisms, and responses to treatments. These biomarkers provide insights into gene expression levels, functionality, and regulation. The increasing prevalence of chronic diseases like cancer, cardiovascular issues, and neurological disorders has heightened the demand for genomic biomarkers. Additionally, greater government funding in healthcare has spurred research and development in this field. Innovations from various companies, particularly those integrating artificial intelligence, are broadening the applications of genomic biomarkers. Moreover, the rising awareness of the importance of early disease detection significantly contributes to market growth.Key Drivers of the Genomic Biomarkers Market:

• Rising Cancer Incidence: The global surge in cancer cases is a major driver for genomic biomarker diagnostics. For example, the National Center for Health Statistics estimates that in 2023, there will be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the U.S., highlighting the urgent need for effective cancer treatment strategies that utilize genomic biomarkers for personalized medicine.
• Recent Developments: In June 2023, Invivoscribe collaborated with Complete Genomics to create and market biomarker tests using next-generation sequencing platforms. These tests aim to improve upfront screening and monitoring for measurable residual disease (MRD), representing a significant advancement in oncology.

Geographical Trends Influencing the Genomic Biomarkers Market:The market is segmented by regions such as North America, South America, Europe, the Middle East and Africa, and Asia Pacific:

• Asia Pacific Growth: Key countries like China, Japan, India, and South Korea are significant contributors in this region. India alone is projected to have 1,461,427 new cancer cases in 2022, with estimates suggesting a cancer burden of 29.8 million by 2025 according to the Indian Council of Medical Research. This dramatic rise is fueling the adoption of genomic biomarkers.
• North America Dominance: North America is expected to maintain a considerable share of the genomic biomarkers market due to leading industry players like MEDiC Life Sciences and Illumina Inc., along with ongoing research efforts in the region.

Overall, the genomic biomarkers market is set for substantial growth driven by the increasing incidence of chronic diseases and advancements in personalized medicine technologies.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The genomic biomarkers market has been segmented as following:

By Type

• Predictive Biomarkers
• Prognostic Biomarkers

By Indication

• Oncology
• Cardiovascular diseases
• Neurological diseases
• Renal Disorders
• Others

By End User

• Hospitals
• Diagnostic Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process
• 2.3. Data Validation

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Supplier
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. GENOMIC BIOMARKERS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Predictive Biomarkers
• 5.3. Prognostic Biomarkers

6. GENOMIC BIOMARKERS MARKET BY INDICATION

• 6.1. Introduction
• 6.2. Oncology
• 6.3. Cardiovascular diseases
• 6.4. Neurological diseases
• 6.5. Renal Disorders
• 6.6. Others

7. GENOMIC BIOMARKERS MARKET BY END USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Diagnostic Centers
• 7.4. Others

8. GENOMIC BIOMARKERS MARKET BY GEOGRAPHY

• 8.1. Global Overview
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. United Arab Emirates
  • 8.5.3. Others
• 8.6. Asia-Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Almac Group
• 10.2. Bio-Rad Laboratories Inc.
• 10.3. Eurofins Scientific
• 10.4. Myriad Genetics Inc
• 10.5. QIAGEN
• 10.6. Thermo Fisher Scientific Inc
• 10.7. Illumina, Inc.
• 10.8. REVEAL GENOMICS, S.L.
• 10.9. Guardant Health
• 10.10. Complete Genomics Incorporated